• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Intertek banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Positive Phase 2 results for Lightlake’s naloxone nasal spray

Lightlake Therapeutics has announced what it called “very encouraging preliminary results” from a Phase 2 clinical trial of its naloxone nasal spray for the treatment of binge eating disorder. According to the company, the randomized, double-blind, placebo controlled trial demonstrated a 56% greater reduction in the amount of time that patients who received the spray spent binge eating compared to patients who received a placebo nasal spray, with the effect increasing over time. The naloxone group also showed a significant reduction in body mass index over the second half of the trial.

Lightlake Chief Scientific Officer David Sinclair said, “We are pleased that the data showed that there is an ‘extinction curve’ – where the benefits of the drug therapy improved over time. We know from our earlier research that permitting people to engage in their problematic behavior – here binge eating – while at the same time receiving drug therapy, results in the person losing interest in that behavior, essentially ‘extinguishing’ binge eating.”

CEO Roger Crystal commented, “We are very pleased with the preliminary results of this study, and we will continue to conduct further evaluation on the additional data captured in the study. Lightlake is committed to research that can help us advance our treatment of BED and other addictive behaviors – disorders that affect millions of individuals worldwide. The data from this study provides further evidence that naloxone may also be a promising treatment for Bulimia Nervosa, which is another related disease that is covered in our patent portfolio. We will work closely with regulatory authorities, to launch further studies to confirm naloxone as a suitable treatment for Binge Eating Disorder.”

Read the Lightlake press release.

Share

published on August 8, 2012

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Merxin We Make Inhalers banner
    © 2025 OINDPnews